Samsung Biologics Sweeps All Categories at the 'CDMO Leadership Awards'

by Lee Myeonghwan

Published 08 Feb.2023 08:58(KST)

10 Consecutive Years of Awards Since 2013
5th Time Sweeping All Categories
'Champion Award' in Capability, Compatibility, Quality, and Stability Sections

[Asia Economy Reporter Myunghwan Lee] Samsung Biologics announced on the 8th that it won awards in all six evaluation categories at the '2023 CDMO Leadership Awards.' This marks the 10th consecutive year since 2013 and the 5th time sweeping all categories.

Samsung Biologics Plant 3 exterior view. / Photo by Samsung Biologics

The CDMO Leadership Awards is a global ceremony hosted by the U.S.-based life sciences magazine 'Life Science Leader' and the pharmaceutical and bio industry research organization 'Industry Standard Research (ISR),' held annually since 2012.

This year, Samsung Biologics not only received excellence awards in all categories but also simultaneously won 'Champion Awards' in four categories: capability, compatibility, quality, and stability. The Champion Award is the highest honor given only to companies that exceed customer expectations in each category.

The organizers explained that they evaluated 23 detailed criteria across global Contract Development and Manufacturing Organizations (CDMOs) this year and selected awardees in six categories: capability, compatibility, expertise, quality, stability, and service.

Samsung Biologics strengthened its production capacity in the Contract Manufacturing Organization (CMO) sector by partially operating Plant 4, which has the world's largest production capacity of 240,000 liters for a single plant, starting in October last year. In the Contract Development Organization (CDO) sector, it enhanced its portfolio by launching 'S-Dual,' a next-generation bispecific antibody platform with an asymmetric structure that improves production capacity and stability, and 'DevelopPick,' which analyzes and screens the stability of new drug candidate substances.

Samsung Biologics plans to invest 7.5 trillion KRW in the bio business over the next 10 years to continue growth centered on three pillars: production capacity, portfolio, and geographic bases.

John Rim, CEO of Samsung Biologics, said, "Winning the CDMO Leadership Awards for 10 consecutive years, including four Champion Awards this year, is thanks to the strong trust our clients have in Samsung Biologics' CDMO competitiveness. We will continue to do our best to meet customer expectations by expanding production capacity and providing high-quality biopharmaceuticals."

Meanwhile, Samsung Biologics recorded its best-ever performance last year, becoming the first in the domestic pharmaceutical and bio industry to surpass annual sales of 3 trillion KRW.